Navigation Links
uBiome Grant Will Enable UCSF Scientist to Explore ‘Spit Test’ to Predict Blood Infections in Young Bone Marrow Transplant Patients
Date:8/8/2017

uBiome, the leader in microbial genomics, has issued its latest Microbiome Impact Grant award to pediatric dentist and scientist Dr. Jeremy Horst of UCSF School of Medicine, who, along with colleagues in the UCSF Children's Oral Health Research Center, is carrying out research into the use of the oral microbiome as a non-invasive way of predicting and preventing blood infections in immunocompromised young bone marrow transplant patients.

Bone marrow transplants are used in order to replace damaged or diseased cells with non-cancerous stem cells that can, in turn, grow new, healthy cells. These transplants tend to be used when treatments for cancer have destroyed the bone marrow’s normal stem cells. Bone marrow, which is found at the core of bones, is where the body manufactures blood cells.

Bone marrow transplants can be either allogeneic or autologous. Allogeneic transplants occur when bone marrow is received from a donor. In autologous transplants, the patient’s own bone marrow is used, after being collected, frozen, and stored until it is needed – following chemotherapy, for example.

Blood infections pose a considerable risk during bone marrow transplants, so being able to predict and prevent them is critical. Dr. Horst’s study aims to explore the use of the oral microbiome as a predictive diagnostic for blood infections in pediatric patients who are immunocompromised, a common phenomenon during transplant procedures. Having a weakened immune system, technically known as immunodeficiency, is a state in which the immune system’s ability to fight infectious disease and cancer is either compromised or entirely absent.

The potential to use the oral microbiome as a marker for the blood microbiome would offer considerable benefits, particularly because of its non-invasive nature.

Dr. Horst is a Postdoctoral Scholar in the Biochemistry and Biophysics Department at UCSF School of Medicine, specializing in Biochemistry and Infectious Diseases. He received his PhD for studies in Oral and Computational Biology at the University of Washington, after also first gaining his DDS there. This was followed by a residency in Pediatric Dentistry at UCSF. Dr. Horst began his academic studies at UCSD, where he was awarded his BS in Pharmacological Chemistry, a BA in Psychology, and a master’s in Chemistry. He has contributed to 40 scientific papers.

The microbiome is the collective term for the ecosystem of trillions of microorganisms that live in and on the human body. Many play important parts in supporting life. For example, gut bacteria aid digestion and enable the synthesis of vitamins. Pathogenic bacteria, however, can be associated with a range of conditions. uBiome employs precision sequencing™ technology to generate detailed analyses of the human microbiome.

Dr. Jeremy Horst says: “To prepare young patients for bone marrow transplant, their immune systems are temporarily wiped out. Despite our extraordinarily cautious efforts, one third of these children at UCSF Benioff Children’s Hospital get blood infections, and oddly enough, one third of the infections come from bacteria in the dental plaque. We use traditional culture-based diagnostics to understand these infections once they happen, but the advanced technology offered by uBiome may enable us to detect harmful oral bacteria before they endanger the lives of these children - with just a bit saliva.”

Dr. Zachary Apte, co-founder and CTO of uBiome, adds: “After collaborating with him in the past, we’re familiar with Dr. Horst’s work. We think his novel proposal to predict and prevent blood infections in young patients with weakened immune systems using something as simple as a saliva test is very exciting.”

Founded in 2012, uBiome is the world’s leading microbial genomics company. uBiome is funded by Y Combinator, Andreessen Horowitz, 8VC, and other leading investors.

uBiome’s mission is to explore important research questions about the microbiome and to develop accurate and reliable clinical tests based on the microbiome.

Contact:
Julie Taylor
julie(at)ubiome(dot)com
Ph: +1 (415) 212-9214

Read the full story at http://www.prweb.com/releases/2017/08/prweb14568771.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. uBiome and Jackson Laboratory for Genomic Medicine to Study Pathogen Transmission in Geriatric Communities
2. uBiome Publishes Peer-Reviewed Scientific Paper in PLOS ONE on First Version of Technology for Gut Health Screening Test
3. Study on How Marital Stress May Affect the Gut Microbiome with uBiome Microbiome Impact Grant
4. uBiome Announces SmartBiome ID™: Sample-Agnostic Pathogen Detection Platform
5. Boston Children’s Hospital and uBiome to Investigate Premature Births
6. Stanford Medicine and uBiome Investigate Relationship Between Gut Bacteria and Diabetes
7. Dutch Journal of Medical Microbiology Publishes uBiome Science Editor’s Most Recent Microbiome Paper
8. Self-Experimenting Scientist Receives uBiome Grant to Investigate Consequences of Long-Term Antibiotic Use for Skin Conditions
9. uBiome Appoints Boston Children’s Hospital Genomics Expert, Dr. Olaf Bodamer, to its Advisory Board
10. UCSF Researcher to Investigate Diabetes and the Microbiome in Filipino Populations with uBiome Microbiome Impact Grant
11. uBiome Joins Google, SpaceX, and Oculus as 2016 World Technology Award Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... ... September 14, 2017 , ... ... CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials that generate unprecedented ... Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will radically simplify major ...
(Date:9/14/2017)... ... September 14, 2017 , ... AIM Global, the worldwide standards agency for ... won the 2017 Case Study Competition for AIDC. The award is given to ... risk” and push the adoption of automated data collection systems further. The TRACTUS ...
(Date:9/12/2017)... Boston, MA (PRWEB) , ... September 12, 2017 ... ... Physiology Analytics (PPA) and highly scalable cloud-based platform for ambulatory patient monitoring and ... Disruptive Innovations to Advance Clinical Trials conference in Boston. , Launched in ...
(Date:9/12/2017)... ... September 12, 2017 , ... ... 2017-2018 are asked to submit a "pre-proposal” by October 15, prior to completing ... greenlight projects that are aligned with our priorities, and to encourage researchers to ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):